Effect of hydroxychloroquine on prevention of covid-19 virus

Effect of hydroxychloroquine on prevention of covid-19 virus infection among treatment staff in Arash hospital-A double-blind clinical trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120826010664N6

Enrollment

310

Registered

2020-04-05

Start date

2020-03-29

Completion date

Unknown

Last updated

2020-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19 prophylaxis.

Interventions

Intervention 1: Intervention group: Hydroxychloroquine 200 mg tablet of Amin Pharmaceutical, 400 mg daily and once a week for one to three months. (Based on the duration of corona virus epidemic). I

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Treatment staff who are in contact with patients who have at least 3 shift a week in the hospital consent to participate in the study.

Exclusion criteria

Exclusion criteria: History of covid-19 virus infection clinical symptoms such as fever, nausea, dispenea and myalgia in the past two months history of underlying diseases hypersensitivity to hydroxychloroquine G6PD enzyme deficiency

Design outcomes

Primary

Measure	Time frame
Covid-19 infection. Timepoint: One, two and three months after starting the drug. Method of measurement: Covid-19 PCR test and clinical symptoms.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactReihaneh Pirjani MD.

Tehran University of Medical Sciences

pirjani@razi.tums.ac.ir+98 21 7788 3288

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 27, 2026